Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 C2 Pharma Expands Ophthalmic API Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

C2 Pharma Expands Ophthalmic API Portfolio

Launches Naphazoline Hydrochloride that will be produced by CMO partner SMS Lifesciences.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

C2 PHARMA, a global provider of ophthalmic and niche active pharmaceutical ingredients (APIs), has launched its latest API, Naphazoline Hydrochloride. The validation campaign for Naphazoline HCL was completed in June 2024. A Certificate of Suitability (CEP) is under approval while the US-Drug Master File (US-DMF) is planned for submission by November 2024 and the API dossier for Brazil (DIFA) in December 2024.
 
Naphazoline HCL is effective in alleviating red eyes and nasal congestion, making it suitable for both prescription and over-the-counter products. This API will be produced by one of the company’s CMO partners, SMS Lifesciences, headquarted in India. 
 
“We transferred Naphazoline Hydrochloride to SMS Lifesciences to enhance C2 PHARMA’s speed and throughput in developing new API’s and to boost our production capacity,” said James Lawler, General Manager of C2 PHARMA. “GMP samples are now available to our customers worldwide to support their validation efforts.”
 
“We pride ourselves on the quality and reliability of our network of CMO partners. With the addition of SMS Lifesciences, we can speed up the roll-out of our ophthalmic API pipeline,” ssaid, Andrew Badrot, CEO of C2 PHARMA. “The plan is to accelerate the delivery of high-quality and best cost-to-quality active pharmaceutical ingredients to the global market with the upcoming release of Timolol Maleate, Dorzolamide, and Brinzolamide over the next 24 months.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics